Cargando…

Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment

OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigo, T., Casals, M., Caminero, J. A., García-García, J. M., Jiménez-Fuentes, M. A., Medina, J. F., Millet, J. P., Ruiz-Manzano, J., Caylá, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/
https://www.ncbi.nlm.nih.gov/pubmed/27487189
http://dx.doi.org/10.1371/journal.pone.0159925
_version_ 1782446235731361792
author Rodrigo, T.
Casals, M.
Caminero, J. A.
García-García, J. M.
Jiménez-Fuentes, M. A.
Medina, J. F.
Millet, J. P.
Ruiz-Manzano, J.
Caylá, J.
author_facet Rodrigo, T.
Casals, M.
Caminero, J. A.
García-García, J. M.
Jiménez-Fuentes, M. A.
Medina, J. F.
Millet, J. P.
Ruiz-Manzano, J.
Caylá, J.
author_sort Rodrigo, T.
collection PubMed
description OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8–283.4); being retired (HR = 2.4;CI:1.1–5.1); having visited the emergency department (HR = 3.1;CI:1.2–7.7); HIV infection (HR = 3.4;CI:1.6–7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2–3.3) or non-standard treatments (HR = 2.68;CI:1.36–5.25); comprehension difficulties (HR = 2.8;CI:1.3–6.1); and smear-positive sputum (HR = 2.3-CI:1.0–4.8). CONCLUSION: There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs.
format Online
Article
Text
id pubmed-4972388
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49723882016-08-18 Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment Rodrigo, T. Casals, M. Caminero, J. A. García-García, J. M. Jiménez-Fuentes, M. A. Medina, J. F. Millet, J. P. Ruiz-Manzano, J. Caylá, J. PLoS One Research Article OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8–283.4); being retired (HR = 2.4;CI:1.1–5.1); having visited the emergency department (HR = 3.1;CI:1.2–7.7); HIV infection (HR = 3.4;CI:1.6–7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2–3.3) or non-standard treatments (HR = 2.68;CI:1.36–5.25); comprehension difficulties (HR = 2.8;CI:1.3–6.1); and smear-positive sputum (HR = 2.3-CI:1.0–4.8). CONCLUSION: There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs. Public Library of Science 2016-08-03 /pmc/articles/PMC4972388/ /pubmed/27487189 http://dx.doi.org/10.1371/journal.pone.0159925 Text en © 2016 Rodrigo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rodrigo, T.
Casals, M.
Caminero, J. A.
García-García, J. M.
Jiménez-Fuentes, M. A.
Medina, J. F.
Millet, J. P.
Ruiz-Manzano, J.
Caylá, J.
Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title_full Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title_fullStr Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title_full_unstemmed Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title_short Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
title_sort factors associated with fatality during the intensive phase of anti-tuberculosis treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/
https://www.ncbi.nlm.nih.gov/pubmed/27487189
http://dx.doi.org/10.1371/journal.pone.0159925
work_keys_str_mv AT rodrigot factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT casalsm factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT camineroja factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT garciagarciajm factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT jimenezfuentesma factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT medinajf factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT milletjp factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT ruizmanzanoj factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT caylaj factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment
AT factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment